Fulgent Genetics PE Ratio 2015-2024 | FLGT
Current and historical p/e ratio for Fulgent Genetics (FLGT) from 2015 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Fulgent Genetics PE ratio as of November 11, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Fulgent Genetics PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-11-12 | 19.16 | 0.00 | |
| 2024-06-30 | 19.62 | $-5.48 | 0.00 |
| 2024-03-31 | 21.70 | $-5.57 | 0.00 |
| 2023-12-31 | 28.91 | $-5.64 | 0.00 |
| 2023-09-30 | 26.74 | $-2.14 | 0.00 |
| 2023-06-30 | 37.03 | $-1.64 | 0.00 |
| 2023-03-31 | 31.22 | $-0.89 | 0.00 |
| 2022-12-31 | 29.78 | $4.56 | 6.53 |
| 2022-09-30 | 38.12 | $8.70 | 4.38 |
| 2022-06-30 | 54.53 | $12.57 | 4.34 |
| 2022-03-31 | 62.41 | $14.79 | 4.22 |
| 2021-12-31 | 100.59 | $16.38 | 6.14 |
| 2021-09-30 | 89.95 | $19.20 | 4.68 |
| 2021-06-30 | 92.23 | $17.25 | 5.35 |
| 2021-03-31 | 96.62 | $14.80 | 6.53 |
| 2020-12-31 | 52.10 | $8.19 | 6.36 |
| 2020-09-30 | 40.04 | $2.02 | 19.82 |
| 2020-06-30 | 16.00 | $0.12 | 133.33 |
| 2020-03-31 | 10.76 | $0.00 | 0.00 |
| 2019-12-31 | 12.90 | $-0.01 | 0.00 |
| 2019-09-30 | 10.39 | $-0.05 | 0.00 |
| 2019-06-30 | 6.68 | $-0.16 | 0.00 |
| 2019-03-31 | 5.95 | $-0.24 | 0.00 |
| 2018-12-31 | 3.17 | $-0.25 | 0.00 |
| 2018-09-30 | 3.93 | $-0.30 | 0.00 |
| 2018-06-30 | 4.14 | $-0.33 | 0.00 |
| 2018-03-31 | 4.00 | $-0.27 | 0.00 |
| 2017-12-31 | 4.38 | $-0.15 | 0.00 |
| 2017-09-30 | 4.79 | $0.00 | 0.00 |
| 2017-06-30 | 6.39 | $-0.38 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.613B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $11.978B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $6.055B | 188.82 |
| Hims & Hers Health (HIMS) | United States | $5.988B | 154.89 |
| Axonics (AXNX) | United States | $3.602B | 1762.00 |
| IRhythm Technologies (IRTC) | United States | $2.783B | 0.00 |
| Privia Health (PRVA) | United States | $2.736B | 228.00 |
| Enovis (ENOV) | United States | $2.646B | 17.94 |
| Omnicell (OMCL) | United States | $2.263B | 74.03 |
| Azenta (AZTA) | United States | $2.242B | 127.33 |
| 10x Genomics (TXG) | United States | $1.925B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.657B | 0.00 |
| Schrodinger (SDGR) | United States | $1.422B | 0.00 |
| Phreesia (PHR) | United States | $1.252B | 0.00 |
| Standard BioTools (LAB) | United States | $0.830B | 0.00 |
| Talkspace (TALK) | United States | $0.586B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.582B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.508B | 88.00 |
| Health Catalyst (HCAT) | United States | $0.506B | 0.00 |
| Pulmonx (LUNG) | United States | $0.298B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.248B | 0.00 |
| TruBridge (TBRG) | United States | $0.214B | 62.22 |
| P3 Health Partners (PIII) | United States | $0.142B | 0.00 |
| American Well (AMWL) | United States | $0.139B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.106B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.064B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.050B | 0.00 |
| Outset Medical (OM) | United States | $0.045B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.042B | 0.00 |
| CareCloud (CCLD) | United States | $0.042B | 0.00 |
| Movano (MOVE) | United States | $0.028B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.018B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.007B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |